Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

They include semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound). GLP-1 receptor agonists can increase satiety, reduce appetite, and regulate blood sugar levels — all of ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

People with fewer side effects, better results stick with these drugs longer The study analyzed records of more than 125,000 adults who began taking the GLP-1 drugs liraglutide, semaglutide ...

That includes the hippocampus, an area that is damaged early on in Alzheimer’s disease. The data for other medications, including semaglutide and liraglutide, are more mixed. Some experts think that ...

Among GLP-1RAs, liraglutide and semaglutide have particularly shown high efficacy in promoting satiety, reducing appetite, and regulating blood glucose levels. The US Food and Drug Administration ...